Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2020 | Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment | CHEN-HUA LIU ; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; CHUN-JEN LIU ; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; YU-JEN FANG ; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO | Gut | 26 | 27 | |
2017 | Spectroelectrochemical and adhesion properties of chemically synthesized ion conducting poly (vinyl butyral) in Prussian blue and poly (3, 4-ethylenedioxythiophene) laminated electrochromic glazing | Huang L.-M.; Peng C.-Y.; Hu C.-W.; Lu H.-C.; Chen C.-H.; Yang D.-J.; Kuo C.-C.; Ho K.-C. | Solar Energy Materials and Solar Cells | 12 | 10 | |
2020 | Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis c patients: A nationwide real-world Taiwanese cohort (T-COACH) | Tsai P.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Hsieh M.-H.; Huang J.-F.; Dai C.-Y.; Chung W.-L.; Ke C.-L.K.; Yu M.-L.; T-COACH Study Group | Open Forum Infectious Diseases | 3 | 3 | |
2020 | Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis | Hsu W.-F.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Tsai P.-C.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Scientific Reports | 4 | 4 | |
2019 | Taiwan consensus statement on the management of chronic hepatitis B | Chien R.-N.; JIA-HORNG KAO ; Peng C.-Y.; Chen C.-H.; CHUN-JEN LIU ; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; YEN-HSUAN NI ; Chuang W.-L.; Lee C.-M.; Wu J.-C.; PEI-JER CHEN ; Liaw Y.-F. | Journal of the Formosan Medical Association | 56 | 47 | |
2021 | Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients | Liu M.; TAI-CHUNG TSENG ; Jun D.W.; Yeh M.-L.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung M.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO ; Yang H.-I.; Nguyen M.H. | Hepatology International | 15 | 14 | |
2018 | Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study | JIA-HORNG KAO ; Yu M.-L.; Chen C.-Y.; Peng C.-Y.; Chen M.-Y.; Tang H.; Chen Q.; Wu J.J. | Journal of Gastroenterology and Hepatology (Australia) | 15 | 11 | |
2013 | Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir | Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; TUNG-HUNG SU ; TAI-CHUNG TSENG ; Hsu C.-S.; Lin H.H.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 26 | |
2005 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models | Pan S.-L.; JIH-HWA GUH ; Peng C.-Y.; Wang S.-W.; Chang Y.-L.; Cheng F.-C.; Chang J.-H.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 55 | 53 | |
2006 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9 | Liu Y.-N.; Pan S.-L.; Peng C.-Y.; JIH-HWA GUH ; Huang D.-M.; Chang Y.-L.; Lin C.-H.; Pai H.-C.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 39 | 33 | |
2008 | YC-1 induces heat shock protein 70 expression and prevents oxidized LDL-mediated apoptosis in vascular smooth muscle cells | Liu Y.-N.; Pan S.-L.; Peng C.-Y.; Huang D.-Y.; JIH-HWA GUH ; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Shock | 12 | 10 |